Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J M Tourani

Showing results (21-30 of 69) with videos related to

Pageof 7
Sort By:
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interleukin-2 therapy for refractory and relapsing lymphomasJ M Tourani, V Levy, J Briere, et al.
Clinical and Experimental Immunology|May 1, 1990
Actuarial rate of clinical and biological progression in a cohort of 250 HIV-1-seropositive subjects. Laennec HIV Study GroupA Venet, J M Tourani, K Beldjord, et al.
Presse Medicale (Paris, France : 1983)|February 11, 1995
[Interleukin-2 in a hemodialyzed patient with metastatic renal adenocarcinoma]E Suc, S Neuville, J L Lacombe, et al.
The Journal of Infectious Diseases|November 1, 1993
High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type 1-related diseasesW Lu, F Grassi, J M Tourani, et al.
The Journal of Allergy and Clinical Immunology|January 1, 1992
Elevation of IgE in HIV-infected subjects: a marker of poor prognosisD Israël-Biet, F Labrousse, J M Tourani, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Annals of Neurology|February 16, 1999
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodiesB Benyahia, R Liblau, H Merle-Béral, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2013
Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumoursJ P Delord, J M Tourani, F Lefresne, et al.
AIDS (London, England)|November 1, 1993
Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patientsW Lu, J W Shih, J M Tourani, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancerM Krzakowski, J Bennouna, E Dansin, et al.
Pageof 7

Showing results (21-30 of 69) with videos related to

Sort By:
Pageof 7
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Interleukin-2 therapy for refractory and relapsing lymphomasJ M Tourani, V Levy, J Briere, et al.
Clinical and Experimental Immunology|May 1, 1990
Actuarial rate of clinical and biological progression in a cohort of 250 HIV-1-seropositive subjects. Laennec HIV Study GroupA Venet, J M Tourani, K Beldjord, et al.
Presse Medicale (Paris, France : 1983)|February 11, 1995
[Interleukin-2 in a hemodialyzed patient with metastatic renal adenocarcinoma]E Suc, S Neuville, J L Lacombe, et al.
The Journal of Infectious Diseases|November 1, 1993
High concentration of peripheral blood mononuclear cells harboring infectious virus correlates with rapid progression of human immunodeficiency virus type 1-related diseasesW Lu, F Grassi, J M Tourani, et al.
The Journal of Allergy and Clinical Immunology|January 1, 1992
Elevation of IgE in HIV-infected subjects: a marker of poor prognosisD Israël-Biet, F Labrousse, J M Tourani, et al.
British Journal of Cancer|March 18, 2004
Safety and efficacy of subcutaneous and continuous intravenous infusion rIL-2 in patients with metastatic renal cell carcinomaP F Geertsen, M E Gore, S Negrier, et al.
Annals of Neurology|February 16, 1999
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodiesB Benyahia, R Liblau, H Merle-Béral, et al.
Cancer Chemotherapy and Pharmacology|January 10, 2013
Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumoursJ P Delord, J M Tourani, F Lefresne, et al.
AIDS (London, England)|November 1, 1993
Lack of isolate-specific neutralizing activity is correlated with an increased viral burden in rapidly progressing HIV-1-infected patientsW Lu, J W Shih, J M Tourani, et al.
Cancer Chemotherapy and Pharmacology|November 14, 2013
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancerM Krzakowski, J Bennouna, E Dansin, et al.
Pageof 7